You are using an outdated browser. Please upgrade your browser to improve your experience.

B-cell chronic lymphocytic leukemia

Disease Summary
Associated Targets (600)
Tbio

403

Tchem

102

Tdark

48

Tclin

47


Explore Associated Targets
Mondo Description B-cell chronic lymphocytic leukemia (B-CLL) is a type of B-cell non-Hodgkin lymphoma, and the most common form of leukemia in Western countries, affecting elderly adults (mean age of 67 and 72 years) with a slight male predominance (1.7:1), and characterized by a highly variable clinical presentation that can include asymptomatic disease or non-specific B-symptoms such as unintentional weight loss, severe fatigue, fever (without evidence of infection), and night sweats as well as cervical lymphadenopathy, splenomegaly and frequent infections. Some patients can also develop autoimmune complications such as autoimmune hemolytic anemia or immune thrombocytopenia. The clinical course is extremely heterogeneous with survival ranging from a few months to several decades.
Uniprot Description A chronic leukemia in which functionally incompetent B-lymphocytes progressively accumulate in the bone marrow, blood, and lymphoid tissues. The clinical evolution of the disorder is heterogeneous, with some patients having indolent disease and others having aggressive disease and short survival.
Disease Ontology Description A lymphoblastic leukemia characterized by over production of B-cells and their accumulation in bone marrow and blood.
Mondo Term and Equivalent IDs
MONDO:0004948:  B-cell chronic lymphocytic leukemia
EFO:0000095: 
GARD:0006104: 
MESH:D015451: 
NCIT:C3163: 
Orphanet:67038: 
UMLS:C0023434: 
UMLS:C0855095: 
GWAS Targets (255)
Target
TDL
Study Count
SNP Count
Beta Count
Odds Ratio
Evidence (Mean Rank Score)
Provenance
Tbio
6
3
0
1.6
96.4
Tdark
6
5
0
1.4
93.7
Tchem
6
4
0
1.4
93
Tbio
5
4
0
1.3
92.6
Tbio
6
3
0
1.4
90.7
Target
TDL
Beta Count
Odds Ratio
Evidence (Mean Rank Score)
Provenance
Tbio
0
1.6
96.4
Tdark
0
1.4
93.7
Tchem
0
1.4
93
Tbio
0
1.3
92.6
Tbio
0
1.4
90.7
Target Novelty (Tin-x)